Most Recent Flipbooks
Quarterly Report 2018 Q3
Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.
Quarterly Report Q2 2018
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018